Blueprint Medicines Stock Price, News & Analysis (NASDAQ:BPMC)

$81.84 +0.40 (+0.49 %)
(As of 02/21/2018 01:30 PM ET)
Previous Close$81.84
Today's Range$80.11 - $85.00
52-Week Range$32.43 - $92.50
Volume402,600 shs
Average Volume322,968 shs
Market Capitalization$3.49 billion
P/E Ratio-26.57
Dividend YieldN/A
Beta1.16

About Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines logoBlueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580

Debt

Debt-to-Equity Ratio0.02%
Current Ratio11.28%
Quick Ratio11.28%

Price-To-Earnings

Trailing P/E Ratio-26.5689149560117
Forward P/E Ratio-21.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.77 million
Price / Sales126.37
Cash FlowN/A
Price / CashN/A
Book Value$6.59 per share
Price / Book12.42

Profitability

Trailing EPS($3.41)
Net Income$-72,490,000.00
Net Margins-437.83%
Return on Equity-43.11%
Return on Assets-34.38%

Miscellaneous

Employees106
Outstanding Shares42,880,000

Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) posted its earnings results on Wednesday, February, 21st. The biotechnology company reported ($1.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.07) by $0.16. The biotechnology company had revenue of $1.63 million for the quarter, compared to analyst estimates of $5.28 million. Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The company's quarterly revenue was down 78.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.75) earnings per share. View Blueprint Medicines' Earnings History.

When will Blueprint Medicines make its next earnings announcement?

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Blueprint Medicines.

Where is Blueprint Medicines' stock going? Where will Blueprint Medicines' stock price be in 2018?

10 Wall Street analysts have issued twelve-month price objectives for Blueprint Medicines' shares. Their predictions range from $56.00 to $99.00. On average, they anticipate Blueprint Medicines' share price to reach $83.78 in the next twelve months. View Analyst Ratings for Blueprint Medicines.

What are Wall Street analysts saying about Blueprint Medicines stock?

Here are some recent quotes from research analysts about Blueprint Medicines stock:

  • 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (1/15/2018)
  • 2. Cowen Inc analysts commented, "We maintain our BUY rating following the Q3/17 results. Histogenics reported zero revenue and a diluted net loss of $5.1M, compared to CG/ consensus of $6.5M/$6.3M net loss, and LPS of $(0.23), compared with CG/consensus estimate of $(0.29)/$(0.28). As anticipated, the Q3 call was largely uneventful as Histogenics awaits one-year data from the NeoCart Phase 3 clinical trial. Management noted that 65% of patients are now at the one-year mark and reiterated their expectation for one-year data to be announced in Q3/18." (11/10/2017)

Who are some of Blueprint Medicines' key competitors?

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the folowing people:

  • Daniel S. Lynch, Chairman of the Board (Age 59)
  • Jeffrey W. Albers, President, Chief Executive Officer, Director (Age 46)
  • Tracey L. Mccain, executive vice president and chief legal (Age 49)
  • Marion Dorsch Ph.D., Chief Scientific Officer (Age 52)
  • Michael Landsittel, Vice President, Finance (Age 45)
  • Anthony L. Boral M.D. Ph.D., Chief Medical Officer (Age 54)
  • Kathryn Haviland, Chief Business Officer (Age 41)
  • Alexis Borisy, Director (Age 45)
  • Lonnel Coats, Independent Director (Age 52)
  • George D. Demetri, Independent Director (Age 60)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Blueprint Medicines stock?

Blueprint Medicines' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.19%), OppenheimerFunds Inc. (3.81%), Perceptive Advisors LLC (2.66%), TimesSquare Capital Management LLC (2.58%), Alliancebernstein L.P. (2.03%) and BVF Inc. IL (1.79%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Christoph Lengauer, Daniel Lynch, Jeffrey W Albers, Kate Haviland, Kevin P Starr, Marion Dorsch, Mark J Levin and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines.

Who sold Blueprint Medicines stock? Who is selling Blueprint Medicines stock?

Blueprint Medicines' stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Alliancebernstein L.P., Two Sigma Investments LP, Jennison Associates LLC, Foundry Partners LLC, First Trust Advisors LP, Wells Fargo & Company MN and Metropolitan Life Insurance Co. NY. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Daniel Lynch, Jeffrey W Albers, Kate Haviland, Marion Dorsch and Mark J Levin. View Insider Buying and Selling for Blueprint Medicines.

Who bought Blueprint Medicines stock? Who is buying Blueprint Medicines stock?

Blueprint Medicines' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, TimesSquare Capital Management LLC, OppenheimerFunds Inc., Artal Group S.A., BlackRock Inc., Driehaus Capital Management LLC, Monashee Investment Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Blueprint Medicines.

How do I buy Blueprint Medicines stock?

Shares of Blueprint Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of Blueprint Medicines stock can currently be purchased for approximately $81.84.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $3.49 billion and generates $27.77 million in revenue each year. The biotechnology company earns $-72,490,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Blueprint Medicines employs 106 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 38 SIDNEY STREET SUITE 200, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]


MarketBeat Community Rating for Blueprint Medicines (BPMC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Blueprint Medicines (NASDAQ:BPMC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $83.78$83.78$70.47$50.03
Price Target Upside: 16.58% upside16.58% upside3.14% upside17.93% upside

Blueprint Medicines (NASDAQ:BPMC) Consensus Price Target History

Price Target History for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ:BPMC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017Goldman Sachs GroupBoost Price TargetBuy -> Buy$82.00 -> $99.00HighView Rating Details
12/10/2017Raymond James FinancialSet Price TargetBuy$82.00HighView Rating Details
12/11/2017JMP SecuritiesBoost Price TargetOutperform$88.00 -> $97.00HighView Rating Details
11/10/2017CowenReiterated RatingBuyN/AView Rating Details
11/6/2017WedbushReiterated RatingOutperform$70.00 -> $82.00N/AView Rating Details
11/1/2017Canaccord GenuityReiterated RatingBuy$66.00 -> $80.00N/AView Rating Details
10/23/2017Morgan StanleyBoost Price TargetOverweight$45.00 -> $78.00N/AView Rating Details
9/29/2017DA DavidsonInitiated CoverageBuy$90.00HighView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy -> Buy$90.00HighView Rating Details
9/5/2017Jefferies GroupReiterated RatingBuy$56.00MediumView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$54.00 -> $37.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Blueprint Medicines (NASDAQ:BPMC) Earnings History and Estimates Chart

Earnings by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ BPMC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018Q4 2017($1.07)($1.23)$5.28 million$1.63 millionViewN/AView Earnings Details
10/31/2017Q3 2017($0.90)($0.96)$5.35 million$8.07 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.75)($0.86)$5.96 million$5.89 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.73)($0.84)$6.02 million$5.84 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.76)($0.75)$6.31 million$7.69 millionViewListenView Earnings Details
11/10/2016Q316($0.77)($0.62)$6.06 million$6.16 millionViewListenView Earnings Details
8/9/2016Q216($0.73)($0.70)$4.41 million$7.07 millionViewListenView Earnings Details
5/10/2016Q116($0.70)($0.57)$3.24 million$6.90 millionViewListenView Earnings Details
3/11/2016Q415($0.53)($0.58)$2.85 million$4.64 millionViewN/AView Earnings Details
11/9/2015Q3($0.54)($0.47)$1.83 million$3.43 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.44)($0.81)$0.94 million$2.69 millionViewN/AView Earnings Details
6/11/2015Q1 2015($6.20)($8.23)$0.94 million$0.65 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Blueprint Medicines (NASDAQ:BPMC) Earnings Estimates

2018 EPS Consensus Estimate: ($3.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.83)($0.83)($0.83)
Q2 20181($0.88)($0.88)($0.88)
Q3 20181($1.03)($1.03)($1.03)
Q4 20181($1.23)($1.23)($1.23)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Blueprint Medicines (NASDAQ:BPMC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Blueprint Medicines (NASDAQ BPMC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 89.28%
Insider Trades by Quarter for Blueprint Medicines (NASDAQ:BPMC)
Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ BPMC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/14/2018Daniel LynchDirectorSell12,500$80.42$1,005,250.00174,342View SEC Filing  
2/12/2018Daniel LynchDirectorSell17,500$74.84$1,309,700.00202,812View SEC Filing  
2/12/2018Kate HavilandInsiderSell6,775$74.93$507,650.7512,649View SEC Filing  
11/21/2017Marion DorschInsiderSell18,334$65.45$1,199,960.3018,334View SEC Filing  
11/15/2017Daniel LynchDirectorSell5,000$63.38$316,900.00View SEC Filing  
11/6/2017Anthony L BoralInsiderSell5,000$70.40$352,000.00View SEC Filing  
11/6/2017Jeffrey W AlbersCEOSell30,000$70.31$2,109,300.00View SEC Filing  
10/5/2017Kate HavilandInsiderSell5,449$66.44$362,031.56View SEC Filing  
9/18/2017Daniel LynchDirectorSell2,500$60.00$150,000.00209,342View SEC Filing  
9/18/2017Kate HavilandInsiderSell6,356$60.03$381,550.686,356View SEC Filing  
8/9/2017Anthony L BoralInsiderSell5,000$48.60$243,000.005,000View SEC Filing  
8/8/2017Jeffrey W AlbersCEOSell30,000$49.62$1,488,600.0018,272View SEC Filing  
8/7/2017Jeffrey W AlbersCEOSell20,000$49.08$981,600.0018,272View SEC Filing  
7/5/2017Daniel LynchDirectorSell7,500$55.06$412,950.00211,842View SEC Filing  
7/5/2017Kate HavilandInsiderSell7,265$54.66$397,104.907,265View SEC Filing  
6/28/2017Daniel LynchDirectorSell32,500$50.28$1,634,100.00View SEC Filing  
6/28/2017Jeffrey W AlbersCEOSell20,000$50.47$1,009,400.0047,920View SEC Filing  
6/28/2017Kate HavilandInsiderSell6,357$50.00$317,850.006,357View SEC Filing  
3/16/2017Mark J LevinMajor ShareholderSell30,000$40.88$1,226,400.00116,444View SEC Filing  
2/7/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell1,000,000$35.28$35,280,000.00View SEC Filing  
12/19/2016Kevin P. StarrMajor ShareholderSell106,489$28.19$3,001,924.91View SEC Filing  
12/1/2016Daniel LynchDirectorSell200$30.02$6,004.00255,694View SEC Filing  
10/13/2016Daniel LynchDirectorSell21,800$30.02$654,436.00View SEC Filing  
8/8/2016Jeffrey W AlbersCEOSell17,000$22.86$388,620.0076,494View SEC Filing  
6/3/2016Jeffrey W AlbersCEOSell17,000$20.03$340,510.0092,486View SEC Filing  
4/13/2016Christoph LengauerInsiderSell15,872$20.01$317,598.7256,657View SEC Filing  
4/12/2016Christoph LengauerInsiderSell18,853$20.14$379,699.4282,845View SEC Filing  
4/6/2016Jeffrey W AlbersCEOSell17,000$20.42$347,140.00109,486View SEC Filing  
12/17/2015Christoph LengauerinsiderSell31,119$25.05$779,530.9572,215View SEC Filing  
11/27/2015Fmr LlcInsiderSell287,415$21.48$6,173,674.20View SEC Filing  
11/24/2015Fmr LlcInsiderSell161,271$20.14$3,247,997.94View SEC Filing  
11/23/2015Fmr LlcInsiderSell189,572$20.15$3,819,875.80View SEC Filing  
11/19/2015Fmr LlcInsiderSell237,218$19.76$4,687,427.68View SEC Filing  
11/17/2015Fmr LlcInsiderSell27,490$20.60$566,294.00View SEC Filing  
11/3/2015Christoph LengauerinsiderSell84,998$21.05$1,789,207.90103,334View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Blueprint Medicines (NASDAQ BPMC) News Headlines

Source:
DateHeadline
Blueprint Medicines (BPMC) Posts Quarterly  Earnings Results, Misses Expectations By $0.16 EPSBlueprint Medicines (BPMC) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS
www.americanbankingnews.com - February 21 at 9:44 AM
Blueprint Medicines Corp. to Host Earnings CallBlueprint Medicines Corp. to Host Earnings Call
finance.yahoo.com - February 21 at 9:31 AM
 Brokerages Expect Blueprint Medicines Corp (BPMC) Will Announce Quarterly Sales of $5.09 Million Brokerages Expect Blueprint Medicines Corp (BPMC) Will Announce Quarterly Sales of $5.09 Million
www.americanbankingnews.com - February 19 at 1:48 AM
Zacks: Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Announce Earnings of -$1.07 Per ShareZacks: Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Announce Earnings of -$1.07 Per Share
www.americanbankingnews.com - February 17 at 11:16 PM
Daniel Lynch Sells 12,500 Shares of Blueprint Medicines Corp (BPMC) StockDaniel Lynch Sells 12,500 Shares of Blueprint Medicines Corp (BPMC) Stock
www.americanbankingnews.com - February 16 at 9:26 PM
Blueprint Medicines (BPMC) Set to Announce Quarterly Earnings on WednesdayBlueprint Medicines (BPMC) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 15 at 8:14 PM
Insider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 6,775 Shares of StockInsider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 6,775 Shares of Stock
www.americanbankingnews.com - February 14 at 6:21 PM
Daniel Lynch Sells 17,500 Shares of Blueprint Medicines Corp (BPMC) StockDaniel Lynch Sells 17,500 Shares of Blueprint Medicines Corp (BPMC) Stock
www.americanbankingnews.com - February 14 at 6:19 PM
Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018
finance.yahoo.com - February 14 at 9:10 AM
Head to Head Contrast: Blueprint Medicines (BPMC) vs. Crispr Therapeutics (CRSP)Head to Head Contrast: Blueprint Medicines (BPMC) vs. Crispr Therapeutics (CRSP)
www.americanbankingnews.com - February 11 at 11:12 AM
Analyzing Blueprint Medicines (BPMC) and Iqvia (IQV)Analyzing Blueprint Medicines (BPMC) and Iqvia (IQV)
www.americanbankingnews.com - February 8 at 5:10 AM
Analyzing Blueprint Medicines (BPMC) and Concert Pharmaceuticals (CNCE)Analyzing Blueprint Medicines (BPMC) and Concert Pharmaceuticals (CNCE)
www.americanbankingnews.com - February 7 at 9:52 AM
Blueprint Medicines Corp (BPMC) Given Consensus Rating of "Buy" by AnalystsBlueprint Medicines Corp (BPMC) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 6 at 9:14 AM
Celyad (CYAD) & Blueprint Medicines (BPMC) Head-To-Head AnalysisCelyad (CYAD) & Blueprint Medicines (BPMC) Head-To-Head Analysis
www.americanbankingnews.com - February 2 at 7:08 PM
 Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Post Quarterly Sales of $5.09 Million Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Post Quarterly Sales of $5.09 Million
www.americanbankingnews.com - February 2 at 4:26 AM
Blueprint Medicines Target of Unusually Large Options Trading (BPMC)Blueprint Medicines Target of Unusually Large Options Trading (BPMC)
www.americanbankingnews.com - January 25 at 2:34 AM
Blueprint Medicines (BPMC) Rating Increased to Buy at Zacks Investment ResearchBlueprint Medicines (BPMC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM
Zacks: Brokerages Expect Blueprint Medicines Corp (BPMC) Will Post Earnings of -$1.07 Per ShareZacks: Brokerages Expect Blueprint Medicines Corp (BPMC) Will Post Earnings of -$1.07 Per Share
www.americanbankingnews.com - January 15 at 1:10 AM
Blueprint Medicines Corp (BPMC) Given Consensus Rating of "Buy" by BrokeragesBlueprint Medicines Corp (BPMC) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 12 at 8:02 AM
Zacks Investment Research Lowers Blueprint Medicines (BPMC) to HoldZacks Investment Research Lowers Blueprint Medicines (BPMC) to Hold
www.americanbankingnews.com - January 11 at 6:20 PM
Blueprint Medicines (BPMC) Upgraded to "Buy" at Zacks Investment ResearchBlueprint Medicines (BPMC) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 8 at 7:52 PM
Head to Head Analysis: Blueprint Medicines (BPMC) and SAGE Therapeutics (SAGE)Head to Head Analysis: Blueprint Medicines (BPMC) and SAGE Therapeutics (SAGE)
www.americanbankingnews.com - January 6 at 1:36 PM
Zacks: Analysts Anticipate Blueprint Medicines Corporation (BPMC) Will Post Quarterly Sales of $5.09 MillionZacks: Analysts Anticipate Blueprint Medicines Corporation (BPMC) Will Post Quarterly Sales of $5.09 Million
www.americanbankingnews.com - December 31 at 10:28 AM
Zacks: Analysts Expect Blueprint Medicines Corporation (BPMC) to Post -$1.07 Earnings Per ShareZacks: Analysts Expect Blueprint Medicines Corporation (BPMC) to Post -$1.07 Earnings Per Share
www.americanbankingnews.com - December 29 at 5:26 AM
Reviewing Blueprint Medicines (BPMC) and Its RivalsReviewing Blueprint Medicines (BPMC) and Its Rivals
www.americanbankingnews.com - December 28 at 1:13 PM
Blueprint Medicines (BPMC) and Its Competitors Head to Head ReviewBlueprint Medicines (BPMC) and Its Competitors Head to Head Review
www.americanbankingnews.com - December 23 at 11:18 PM
Reviewing Blueprint Medicines (BPMC) & Its PeersReviewing Blueprint Medicines (BPMC) & Its Peers
www.americanbankingnews.com - December 23 at 1:12 PM
Blueprint Medicines Corporation (BPMC) Given Consensus Recommendation of "Buy" by AnalystsBlueprint Medicines Corporation (BPMC) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 18 at 8:30 AM
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common StockBlueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
finance.yahoo.com - December 15 at 5:49 PM
Traders Buy Large Volume of Call Options on Blueprint Medicines (BPMC)Traders Buy Large Volume of Call Options on Blueprint Medicines (BPMC)
www.americanbankingnews.com - December 15 at 3:38 AM
Blueprint Medicines Corporation (BPMC) Expected to Announce Quarterly Sales of $4.32 MillionBlueprint Medicines Corporation (BPMC) Expected to Announce Quarterly Sales of $4.32 Million
www.americanbankingnews.com - December 14 at 6:50 PM
FY2018 Earnings Forecast for Blueprint Medicines Corporation (BPMC) Issued By WedbushFY2018 Earnings Forecast for Blueprint Medicines Corporation (BPMC) Issued By Wedbush
www.americanbankingnews.com - December 14 at 3:22 PM
ETFs with exposure to Blueprint Medicines Corp. : December 13, 2017ETFs with exposure to Blueprint Medicines Corp. : December 13, 2017
finance.yahoo.com - December 13 at 5:23 PM
Goldman Hopes Biotech Investors Keep Singing About These BluesGoldman Hopes Biotech Investors Keep Singing About These Blues
finance.yahoo.com - December 12 at 5:39 PM
Company News For Dec 12, 2017Company News For Dec 12, 2017
finance.yahoo.com - December 12 at 5:39 PM
Blueprint Medicines Announces Proposed Public Offering of Shares of Common StockBlueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
finance.yahoo.com - December 11 at 5:25 PM
Goldman Sachs Group Boosts Blueprint Medicines (BPMC) Price Target to $99.00Goldman Sachs Group Boosts Blueprint Medicines (BPMC) Price Target to $99.00
www.americanbankingnews.com - December 11 at 4:28 PM
Raymond James Financial Reiterates $82.00 Price Target for Blueprint Medicines (BPMC)Raymond James Financial Reiterates $82.00 Price Target for Blueprint Medicines (BPMC)
www.americanbankingnews.com - December 11 at 11:50 AM
Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech MoversBlueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers
finance.yahoo.com - December 11 at 10:21 AM
What does Blueprint Medicines Corporation’s (BPMC) Balance Sheet Tell Us Abouts Its Future?What does Blueprint Medicines Corporation’s (BPMC) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - December 11 at 10:21 AM
Blueprint Medicines (BPMC) Price Target Raised to $97.00Blueprint Medicines (BPMC) Price Target Raised to $97.00
www.americanbankingnews.com - December 11 at 9:52 AM
Blueprint Medicines (BPMC) Lowered to Hold at BidaskClubBlueprint Medicines (BPMC) Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 10 at 5:14 PM
Blueprint Medicines (BPMC) and The Competition Head to Head ContrastBlueprint Medicines (BPMC) and The Competition Head to Head Contrast
www.americanbankingnews.com - December 10 at 3:30 PM
Comparing Blueprint Medicines (BPMC) and The CompetitionComparing Blueprint Medicines (BPMC) and The Competition
www.americanbankingnews.com - December 8 at 5:14 PM
Blueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : December 7, 2017Blueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : December 7, 2017
finance.yahoo.com - December 7 at 5:38 PM
Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : December 6, 2017Blueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : December 6, 2017
finance.yahoo.com - December 6 at 9:48 AM
Blueprint Medicines (BPMC) Stock Rating Lowered by ValuEngineBlueprint Medicines (BPMC) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 3 at 9:26 PM
Head to Head Comparison: Blueprint Medicines (BPMC) versus Its RivalsHead to Head Comparison: Blueprint Medicines (BPMC) versus Its Rivals
www.americanbankingnews.com - December 3 at 11:42 AM
ETFs with exposure to Blueprint Medicines Corp. : November 29, 2017ETFs with exposure to Blueprint Medicines Corp. : November 29, 2017
finance.yahoo.com - November 29 at 5:32 PM
Reviewing Blueprint Medicines (BPMC) and Advaxis (ADXS)Reviewing Blueprint Medicines (BPMC) and Advaxis (ADXS)
www.americanbankingnews.com - November 27 at 5:28 AM

SEC Filings

Blueprint Medicines (NASDAQ:BPMC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Blueprint Medicines (NASDAQ:BPMC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Blueprint Medicines (NASDAQ BPMC) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.